| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | GZMM |
| Uniprot No | P51124 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-257aa |
| 氨基酸序列 | MEACVSSLLVLALGALSVGSSFGTQIIGGREVIPHSRPYMASLQRNGSHL CGGVLVHPKWVLTAAHCLAQRMAQLRLVLGLHTLDSPGLTFHIKAAIQHP RYKPVPALENDLALLQLDGKVKPSRTIRPLALPSKRQVVAAGTRCSMAGW GLTHQGGRLSRVLRELDLQVLDTRMCNNSRFWNGSLSPSMVCLAADSKDQ APCKGDSGGPLVCGKGRVLAGVLSFSSRVCTDIFKPPVATAVAPYVSWIR KVTGRSA |
| 预测分子量 | 27,5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下为3篇关于GZMM(颗粒酶M)重组蛋白的相关文献摘要信息：
1. **"Granzyme M is a regulatory protease during in vitro and in vivo immune responses"**
- 作者：Spaeny-Dekking et al.
- 摘要：该研究通过重组GZMM蛋白的功能分析，揭示其在体外和体内免疫反应中诱导细胞凋亡的能力，并证明其通过激活caspase非依赖性途径杀伤靶细胞，参与NK细胞介导的细胞毒性调控。
2. **"Structural basis of substrate specificity in human granzymes M and H"**
- 作者：Hou et al.
- 摘要：研究利用重组表达的GZMM蛋白进行晶体结构解析，阐明其对特定底物(如蛋白酶激活受体PAR-1)的切割机制，揭示了GZMM与颗粒酶H(GZMH)在底物选择性和免疫调控中的差异。
3. **"Granzyme M mediates TLR8-driven inflammasome activation in human monocytes"**
- 作者：Shen et al.
- 摘要：通过重组GZMM蛋白的功能实验，发现其在单核细胞中通过切割NLRP3炎症小体关键蛋白，促进TLR8信号触发的炎症反应，为GZMM在感染性疾病中的免疫调节作用提供新证据。
4. **"Recombinant granzyme M induces apoptosis in leukemia cells via mitochondrial damage"**
- 作者：Wang et al.
- 摘要：该研究通过体外表达纯化GZMM重组蛋白，证明其通过破坏线粒体膜电位和释放细胞色素C，选择性诱导白血病细胞凋亡，为开发基于GZMM的肿瘤治疗策略提供实验依据。
注：以上文献信息为基于公开研究领域的模拟概括，实际文献需通过学术数据库(如PubMed)检索确认。
Granzyme M (GZMM), a member of the granzyme family of serine proteases, is primarily expressed by natural killer (NK) cells and cytotoxic T lymphocytes (CTLs). It plays a critical role in immune defense by inducing apoptosis in target cells, particularly during viral infections and tumor surveillance. Unlike other granzymes such as Granzyme B, which relies on caspase-dependent pathways, GZMM triggers cell death through caspase-independent mechanisms, often involving cleavage of substrates like the mitochondrial protein PNPT1 (polyribonucleotide nucleotidyltransferase 1) or components of the endoplasmic reticulum. This unique mode of action allows GZMM to bypass common resistance mechanisms in diseased cells.
Recombinant GZMM protein is produced via genetic engineering, typically using bacterial or mammalian expression systems, to study its biochemical properties and therapeutic potential. Purification techniques such as affinity chromatography ensure high purity and enzymatic activity. Research on recombinant GZMM has shed light on its substrate specificity, structural motifs (e.g., catalytic triad His-Asp-Ser), and interactions with inhibitors like protease inhibitors or proteoglycans. Its ability to induce apoptosis without caspase activation makes it a promising candidate for cancer immunotherapy, especially in tumors resistant to conventional treatments. Additionally, studies explore its role in inflammatory diseases and immune regulation, as dysregulated GZMM expression correlates with autoimmune conditions.
Despite progress, challenges remain in understanding its full biological repertoire, including non-apoptotic functions like cytokine regulation and extracellular matrix remodeling. Ongoing work aims to harness recombinant GZMM for targeted therapies while minimizing off-target effects, balancing its cytotoxic potency with precision.
×
